Clinical Trials Logo

Clinical Trial Summary

Women of late to mid reproductive age may participate in a study using novel methodology to identify subtle changes in the reproductive endocrine axis via daily urine hormone analysis, which may have important implications for reproduction and may signal reproductive senescence.


Clinical Trial Description

Women with a reduced follicular pool either from natural aging or previous chemotherapy, may not have any clinical signs or symptoms and traditional measures of ovarian reserve, such as basal Follicle Stimulating Hormone may be within the normal range. However, there may be alterations in the luteal or follicular phases(shortened follicular phase and luteal insufficiency) due to compromised follicle competency and alterations in the H-P-O axis. Therefore this aim uses novel methodology to identify subtle changes in the reproductive endocrine axis which may have important implications for reproduction and may signal reproductive senescence. Compared to yearly follicular measures of reproductive hormones, daily urine hormone analysis provides a more integrative assessment. Three groups of subjects will be recruited: Group 1: Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment. Group 2: healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy. Group 3: healthy, late reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility. Subjects in all groups must have regular menstrual cycles every 21-35 days, and have a uterus and both ovaries. Each participant will complete daily urinary collections for 2 menstrual cycles to assess reproductive hormones. The ultimate goal of this work is to better estimate the reproductive window, or time to menopause. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03197532
Study type Observational
Source University of Pennsylvania
Contact
Status Completed
Phase
Start date January 2011
Completion date May 2016

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05529940 - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Phase 3
Recruiting NCT02306837 - Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies Phase 2
Completed NCT02771470 - Intestinal Microflora in Lung Cancer After Chemotherapy Phase 1
Completed NCT02454647 - Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients N/A
Completed NCT02454673 - Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer N/A
Completed NCT01432223 - Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab Phase 2
Completed NCT02767388 - Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Recruiting NCT02555592 - Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level N/A
Suspended NCT02121405 - Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM Phase 3
Recruiting NCT02226380 - FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer Phase 2
Completed NCT00911352 - Cryotherapy Intervention for Docetaxel-induced Nail Toxicities Phase 2/Phase 3
Completed NCT03840824 - Blood Spot Self-administered Test and Assay
Active, not recruiting NCT01490060 - Fosaprepitant in Patients Receiving Ifosfamide-based Regimen N/A
Completed NCT02395341 - The Longitudinal Ovarian Reserve Study N/A
Recruiting NCT05268991 - Aging and Frailty Study
Recruiting NCT03885388 - Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6 Phase 2/Phase 3
Completed NCT02375776 - Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention N/A
Enrolling by invitation NCT02074241 - Molecular Markers of Chemosensitivity for Bladder Cancer N/A
Completed NCT01143844 - Assessing Fertility Potential in Female Cancer Survivors
Recruiting NCT02169388 - Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy Phase 1